The new bivalent boosters against COVID-19 have failed to halt omicron infections. However, new technologies are being developed that pave a way forward.
Academic rigour, journalistic flair
Articles on Pfizer-BioNTech vaccine
Displaying 1 - 20 of 148 articles
The CDC’s endorsement of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.
Early on, public health messaging focused on the need for vaccines to combat COVID-19. But far less attention has been given to the role of boosters in preventing deaths and reducing inequities.
It’s natural to have questions about the risks and benefits of COVID vaccines in young children. Here’s what you need to know ahead of Australia’s rollout.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
The FDA’s authorization of COVID-19 shots for children ages 6 months to 4 years will bring relief for millions of parents. Pending CDC endorsement, shots for this group will be available within days.
Pfizer and Moderna have both recently reported results for their COVID-19 vaccines in the youngest children.
The COVID-19 vaccines continue to be effective against severe illness leading to hospitalization and death in all age groups, including children ages 5 to 11.
Moderna will ask the FDA to allow emergency use for its vaccine in children as young as 6 months, a step many parents have been anticipating.
The COVID-19 pandemic has brought immunology terms that are typically relegated to textbooks into our everyday vernacular. These stories helped us make sense of the ever-evolving science.
New research sheds light on how Canadian researchers developed a key component of the mRNA COVID-19 vaccines but failed to share it with the world
Some of the omicron variant’s unique properties – such as its ability to spread rapidly while causing milder COVID-19 infections – could usher in a new phase of the pandemic.
We’re reliant on overseas supply - and the many moving parts of delivery. Each of those parts require staff on the ground – and many workers in this system are likely being affected by Omicron.
The new omicron variant of coronavirus has a number of mutations that may require manufacturers to update vaccines. The unique attributes of mRNA vaccines make updating them fast and easy.
There’s not enough evidence yet to support the AstraZeneca CEO’s statement. But it is theoretically plausible.
The CDC’s COVID-19 vaccine provider agreement prohibits health care professionals from administering the vaccines in people for whom they are not yet authorized or approved. But this departs from longstanding norms.
Pfizer contractor Ventavia denies accusations of scientific misconduct on COVID vaccine trial.
An infectious diseases doctor reviews the evidence, discusses hesitancy and concerns about side-effects and explains the overwhelming case for vaccinating five-to-11-year-olds, including his own son.
When making the decision whether to vaccinate children aged five to 11 against COVID-19, regulators in Canada must rely on sound ethics as well as sound science.
Pediatric clinical trials for the COVID-19 Pfizer vaccine for children ages 5 to 11 have shown that the Pfizer shot is safe and effective.
Top contributors
-
Professor of Medicine, University of Virginia
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Associate Professor of Pediatrics, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Chair in Epidemiology, Deakin University
-
Instructor of Human Immunology, Emory University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Associate Professor in Viral Immunology, University of Birmingham
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
